

[Table of Contents](#)

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 10-QSB

(Mark One)

**QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended
September 30, 2006

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

For the transition period from to

Commission file number 333-131853

CEREPLAST, INC.

(Exact name of registrant as specified in its charter)

Nevada
(State or other Jurisdiction of Incorporation or
Organization)

91-2154289
(IRS Employer Identification No.)

3421-3433 West El Segundo Boulevard
Hawthorne, California 90250
(Address of principal executive offices (zip code))

310-676-5000
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the last 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes No

At November 13, 2006, there were 201,448,222 shares of common stock, \$0.001 par value per share, issued and outstanding.

Transitional small business disclosure format (Check one) YES NO

[Table of Contents](#)

TABLE OF CONTENTS

[PART I — FINANCIAL INFORMATION](#)

0

[ITEM 1. FINANCIAL STATEMENTS](#)

[BALANCE SHEET](#)

[STATEMENTS OF OPERATION](#)

[STATEMENTS OF CASH FLOWS](#)

[NOTES TO THE FINANCIAL STATEMENTS](#)

[ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION](#)

[ITEM 3. CONTROLS AND PROCEDURES](#)

[PART 2 — OTHER INFORMATION](#)

[ITEM 1. LEGAL PROCEEDINGS](#)

[ITEM 2. ISSUANCE OF UNREGISTERED SECURITIES AND USE OF PROCEEDS](#)

[ITEM 3. DEFAULTS UPON SENIOR SECURITIES:](#)

[ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS](#)

[ITEM 5. OTHER INFORMATION](#)

[ITEM 6. EXHIBITS](#)

[SIGNATURES](#)

[EXHIBIT 31.1](#)

[EXHIBIT 32.1](#)

Table of Contents

PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

CEREPLAST, INC.
BALANCE SHEET
SEPTEMBER 30, 2006
(UNAUDITED)

ASSETS	
Current Assets	
Cash	\$ 154,738
Accounts Receivable, Net	124,217
Inventory	936,804
Employee Advances	5,796
Prepaid Expenses	—
Total Current Assets	<u>1,221,555</u>
Property and Equipment	
Property and Equipment	996,372
Accumulated Depreciation and Amortization	<u>(181,632)</u>
Net Property and Equipment	<u>814,740</u>
Other Assets	
Intangibles, Net	25,122
Deposits	<u>26,344</u>
Total Other Assets	<u>51,466</u>
Total Assets	<u><u>\$ 2,087,761</u></u>
LIABILITIES AND SHAREHOLDERS' EQUITY	
Current Liabilities	
Accounts Payable	\$ 224,551
Other Payable	2,121
Accrued Expenses	35,088
Credit Lines	47,468
Note Payable	251,250
Shareholder's Loan	157,908
Capital Leases, Current Portion	11,023
Loan Payable, Current Portion	<u>2,495</u>
Total Current Liabilities	<u>731,904</u>
Long-Term Liabilities	

Capital Leases	125,283
Loan Payable	25,429
Total Long-Term Liabilities	<u>150,712</u>
Total Liabilities	<u>882,616</u>
Shareholders' Equity	
Preferred Stock, \$0.001 par value; 5,000,000 authorized preferred shares	—
Common Stock, \$0.001 par value; 495,000,000 authorized shares; 201,131,189 shares issued and outstanding	201,132
Additional Paid in Capital	7,763,023
Deferred Equity Offering Cost	(3,071,180)
Retained Earnings/(Deficit)	<u>(3,687,830)</u>
Total Shareholders' Equity	<u>1,205,145</u>
Total Liabilities and Shareholders' Equity	<u>\$ 2,087,761</u>

The accompanying notes are an integral part of these financial statements

Table of Contents

CEREPLAST, INC. STATEMENTS OF OPERATION (UNAUDITED)

	Three Months Ended		Nine Months Ended	
	9/30/2006	9/30/2005	9/30/2006	9/30/2005
REVENUES	\$ 169,061	\$ 172,935	\$ 448,910	\$ 464,052
COST OF SALES	93,474	179,229	276,830	418,970
GROSS PROFIT	75,587	(6,294)	172,080	45,082
OPERATING EXPENSES				
Depreciation and Amortization	36,334	6,130	100,877	6,130
Marketing Expense	75,521	—	202,997	—
Professional Fees	125,913	15,135	344,898	15,135
Rent Expense	40,266	5,216	129,926	5,216
Salaries & Wages	403,752	3,918	630,200	3,918
Other Operating Expenses	516,646	194,125	856,295	632,756
TOTAL OPERATING EXPENSES	1,198,432	224,524	2,265,193	663,155
LOSS FROM OPERATIONS BEFORE OTHER INCOME (EXPENSES)	(1,122,845)	(230,818)	(2,093,113)	(618,073)
OTHER INCOME (EXPENSES)				
Interest Income	222	—	6,125	—
Interest Expense	(13,364)	(14,988)	(39,511)	(33,386)
	(13,142)	(14,988)	(33,386)	(33,386)
LOSS BEFORE PROVISIONS FOR TAXES	(1,135,987)	(245,806)	(2,126,499)	(651,459)
Provision for Taxes	—	—	—	—
NET LOSS	\$ (1,135,987)	\$ (245,806)	\$ (2,126,499)	\$ (651,459)
BASIC AND DILUTED LOSS PER SHARE	\$ (0.01)	\$ (0.00)	\$ (0.01)	\$ (0.00)

**WEIGHTED-AVERAGE COMMON
SHARES OUTSTANDING BASIC
AND DILUTED**200,400,921151,590,529198,037,524146,140,443

The accompanying notes are an integral part of these financial statements

Table of Contents

CEREPLAST, INC. STATEMENTS OF CASH FLOWS (UNAUDITED)

	9 Months Ended	
	9/30/2006	9/30/2005
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	\$(2,126,499)	\$(651,459)
Adjustment to reconcile net loss to net cash used in operating activities		
Depreciation and amortization	100,877	31,550
Financing Discount Costs	69,445	
Common stock issued for services	294,630	28,200
(Increase) Decrease in:		
Accounts Receivable	(77,254)	(68,767)
Inventory	(646,699)	46,000
Employee advances	(4,496)	—
Deposits	(3,907)	(32,033)
Prepaid Expenses	172,686	(1,753)
Increase (Decrease) in:		
Accounts Payable	(4,851)	(73,877)
Other Payables	(4,698)	2,920
Accrued Expenses	(72,552)	(19,009)
NET CASH USED IN OPERATING ACTIVITIES	<u>(2,303,318)</u>	<u>(738,228)</u>
NET CASH USED IN INVESTING ACTIVITIES:		
Purchase of property and equipment, and intangibles	(565,335)	(17,700)
NET CASH USED IN INVESTING ACTIVITIES	<u>(565,335)</u>	<u>(17,700)</u>
CASH FLOWS FROM FINANCING ACTIVITIES:		
Bank Overdraft	—	—
Advances from shareholders	38,579	36,838
Payments on advances from shareholders	(6,797)	(45,634)
Advances on Credit Lines	251,250	13,077
Payments on Credit Line	(20,160)	—
Payments on Capital Leases	(30,106)	(31,638)
Proceeds from Notes Payable	—	150,000
Payments on Term Loan Payable	(57,237)	(6,769)
Proceeds from issuance of common stock and subscription receivable	2,341,375	648,423
NET CASH PROVIDED BY FINANCING ACTIVITIES	<u>2,516,904</u>	<u>764,297</u>
NET INCREASE (DECREASE) IN CASH	(351,749)	8,369
CASH, BEGINNING OF PERIOD	<u>506,487</u>	<u>4,705</u>

CASH, END OF PERIOD

\$ 154,738\$ 13,074

SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION

During the nine months ended September 30, 2006, the Company issued 720,690 shares in exchange for a \$625,000 advance on its Equity Line of Financing. During the nine months ended September 30, 2006, the Company paid \$30,589 in interest and during the nine months ended September 30, 2005, the Company paid \$23,927 in interest. During the nine months ended September 30, 2006 and 2005, the Company was not liable for any income tax payments.

SUPPLEMENTAL SCHEDULE OF NON-CASH TRANSACTIONS

During the nine months ended September 30, 2006 the Company issued 5,000,000 shares to secure its Equity Line of Financing, 420,340, valued at \$318,504 for services and cancelled 678,106 shares.

The accompanying notes are an integral part of these financial statements

Table of Contents

CEREPLAST, INC.
NOTES TO THE FINANCIAL STATEMENTS
September 30, 2006

1. ORGANIZATION AND LINE OF BUSINESS

Organization

Cereplast, Inc. (the "Company") was incorporated in the state of Nevada on September 29, 2001. The Company, based in Hawthorne, California, began commercial operations January 1, 2002 to provide products and services for biodegradable packaging and organic waste systems in the food service and beverage industries. In 2005, the Company started to redirect its operations toward resin manufacturing and expanded its operations in renting industrial facility with additional warehouse space.

The accompanying interim unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine month period ended September 30, 2006 are not necessarily indicative of the results that may be expected for the year ending December 31, 2006. For further information, refer to the financial statements for the year ended December 31, 2005 and the notes thereto included in the Company's Annual Report.

Line of Business

The Company had developed a breakthrough technology to produce proprietary bio-based resins, which are used as substitutes for conventional petroleum-based plastics in a variety of applications, including the manufacture of food service items such as utensils, plates, cups, and straws. The Company was validating its technology in selling finished products, but since mid-2005, the Company started its transition to become only a resin manufacturer.

2. CAPITAL STOCK

During the nine months ended September 30, 2006 the Company received funds of \$105,000 for restricted common stock subscribed.

Through a private placement, which was made in reliance upon an exemption from registration under rule 506 of Regulation D promulgated under Section 4(2) of the Securities Act of 1933, 10,710,000 restricted shares of common stock were issued for cash of \$1,326,250.

In April 2006, the Company cancelled 678,106 shares relating to services rendered.

On April 2, 2006, Yanosan Group exercised the option to convert the \$50,000 outstanding principal balance and accrued interest on its Customer Loan into 1,045,000 restricted shares of common stock.

On April 20, 2006, the Company issued 20,000 shares valued at \$16,000 for services.

On September 30, 2006 the Company issued 392,840 shares valued at \$294,630 to various employees and consultants for services rendered.

As of September 30, 2006 the Company received funds of \$625,000 under its Equity Line of Credit Financing.

3. EQUITY LINE OF FINANCING

On February 13, 2006, the Company entered into a \$10,000,000 private equity line of financing agreement with Cumorah Capital, Inc. (the investor), with a commitment period of twenty-four months. Based on the amount of the advance, the Investor can purchase shares of common stock at an exchange rate equal to 90% of the market price during the pricing period. A 5,000,000 shares commitment fee was paid by the Company at time of closing. As of the nine months ended September 30, 2006, the Company received \$625,000 in exchange for 720,698 shares on the equity line and has \$9,375,000 in availability.

4. RELATED PARTY

At September 30, 2006, the shareholder's loan in the amount of \$157,908, is from the shareholders, and bear interest payable at the rate of 6% per annum.

Table of Contents

At September 30, 2006, the Note Payable in the amount of \$251,250, is from Cumorah Capital, Inc., and bears interest payable at the rate of 6% per annum. On or about January 4, 2006, the majority shareholder transferred 2,130,000 shares of common stock to various Transferees and reissued certificates with restrictive transfer legend to the Transferees pursuant to Section 4(1) of the Act.

5. SUBSEQUENT EVENTS

On October 4, 2006, the Company received funds of \$200,000 in exchange for 500,000 restricted shares.

[Table of Contents](#)

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

Cautionary Statements

This Form 10-QSB may contain "forward-looking statements," as that term is used in federal securities laws, about Cereplast, Inc.'s financial condition, results of operations and business. These statements include, among others:

- statements concerning the potential benefits that Cereplast, Inc. (the "Company," "we," or "Cereplast") may experience from its business activities and certain transactions it contemplates or has completed; and
- statements of Cereplast's expectations, beliefs, future plans and strategies, anticipated developments and other matters that are not historical facts. These statements may be made expressly in this Form 10-QSB. You can find many of these statements by looking for words such as "believes," "expects," "anticipates," "estimates," "opines," or similar expressions used in this Form 10-QSB. These forward-looking statements are subject to numerous assumptions, risks and uncertainties that may cause Cereplast's actual results to be materially different from any future results expressed or implied by Cereplast in those statements. The most important facts that could prevent Cereplast from achieving its stated goals include, but are not limited to, the following:
 - (a) volatility or decline of Cereplast's stock price;
 - (b) potential fluctuation in quarterly results;
 - (c) failure of Cereplast to earn revenues or profits;
 - (d) inadequate capital to continue or expand its business, inability to raise additional capital or financing to implement its business plans;
 - (e) failure to commercialize Cereplast's technology or to make sales;
 - (f) changes in demand for Cereplast's products and services;
 - (g) rapid and significant changes in markets;
 - (h) litigation with or legal claims and allegations by outside parties;
 - (i) insufficient revenues to cover operating costs.

There is no assurance that Cereplast will be profitable, Cereplast may not be able to successfully develop, manage or market its products and services, Cereplast may not be able to attract or retain qualified executives and technology personnel, Cereplast may not be able to obtain customers for its products or services, Cereplast's products and services may become obsolete, government regulation may hinder Cereplast's business, additional dilution in outstanding stock ownership may be incurred due to the issuance of more shares, warrants and stock options, or the exercise of outstanding warrants and stock options, and other risks inherent in Cereplast's businesses.

Because the statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by the forward-looking statements. Cereplast cautions you not to place undue reliance on the statements, which speak only as of the date of this Form 10-QSB. The cautionary statements contained or referred to in this section should be considered in connection with any subsequent written or oral forward-looking statements that Cereplast or persons acting on its behalf may issue. Cereplast does not undertake any obligation to review or

confirm analysts' expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this Form 10-QSB, or to reflect the occurrence of unanticipated events.

Current Overview

We are engaged in the development, manufacture and sale of renewable plastic resins which are used as substitutes for conventional, petroleum based plastics in a variety of applications, including the manufacture of food service items such as utensils, plates, cups and straws. Our renewable resins are starch-based and compostable and incorporate resources such as corn, wheat and potato starch, which are also bio-degradable and bio-based.

We develop and manufacture each of our resins at our facility to create various grades of our resins. We then sell our resins to traditional plastic converters. Cereplast resins can be used to substitute for all traditional plastic resins. Each of our resins is truly thermoplastic and are compatible with existing manufacturing processes and equipment for various applications including injection molding, thermoforming, blow molding, extrusions, etc.. As a result, plastic manufacturers do not need to change their equipment in order to accommodate our resins. We believe our resins provide plastic manufacturers with an environmentally safe and economically viable alternative to conventional, petroleum-based plastics.

Table of Contents

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We monitor our estimates on an on-going basis for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are recorded in the period in which they become known. We base our estimates on historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate.

We have identified the policies below as critical to our business operations and the understanding of our results of operations.

Revenue Recognition. Our revenue recognition policies are in compliance with Staff accounting bulletin (SAB) 101. Sales revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations by us exist and collectibility is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue.

Results of Operations for the Three Months and Nine months Ended September 30, 2006 compared to the Three and Nine months Ended September 30, 2005.

Revenues

Revenues decreased by \$3,874, or 2.2%, to \$169,061 for the three months ended September 30, 2006 compared to the three months ended September 30, 2005. Revenues decreased by \$15,142, or 3.3%, to \$448,910 for the nine months ended September 30, 2006 compared to the nine months ended September 30, 2005. The slight decrease in revenue was a result of the Company's strategic decision to focus on increasing resin sales and decreasing finished goods sales.

Cost of Sales

Cost of sales decreased by \$85,755 or 47.8%, to \$93,474 for the three months ended September 30, 2006 compared to the three months ended September 30, 2005. As a percentage of sales, cost of sales was 55.3% for the three months ended September 30, 2006 compared to 103.6% for the three months ended September 30, 2005. Cost of sales decreased by \$142,140 or 33.9%, to \$276,830 for the nine months ended September 30, 2006 compared to the nine months ended September 30, 2005. As a percentage of sales, cost of sales was 61.7% for the nine months ended September 30, 2006 compared to 90.3% for the nine months ended September 30, 2005. The decrease in cost of sales is a result of changes in product mix and operating efficiencies, including the production of resin on site.

Gross Profit

Gross profit increased \$81,881 from (\$6,294) to \$75,587 for the three months ended September 30, 2006 compared to the three months ended September 30, 2005. Gross profit increased \$126,998 or 281.7%, to \$172,080 for the nine months ended September 30, 2006 compared to the nine months ended September 30, 2005. The gross profit margin also increased 294.8% to 38.3% for the nine months ended September 30, 2006 compared to 9.7% for

the nine months ended September 30, 2005, as the Company continues to increase the sale of resin as part of its product mix.

Operation Expenses

General and administrative (“G&A”) expenses increased by \$973,908 or 433.7%, to \$1,198,432 for the three months ended September 30, 2006 compared to the three months ended September 30, 2005. G&A expenses increased by \$1,602,038, or 241.6%, to \$2,265,193 for the nine months ended September 30, 2006 compared to the nine months ended September 30, 2005. This increase in G&A expenses for the six month ended September 30, 2005 was a result of an increase in staff salaries, marketing expense, professional and consulting fees, as well as other general expenses.

Research and Development

Research and development (“R&D”) costs increased by \$39,424 or 237.2%, to \$56,044 for the three months ended September 30, 2006 compared to the three months ended September 30, 2005. Research and development (“R&D”) costs increased by \$85,768 or 516.1%, to \$102,388 for the nine months ended September 30, 2006 compared to the nine months ended September 30, 2005. The increase in R&D costs was a result of Cereplast’s continued effort to expand its in-house resin manufacturing capabilities by developing and offering various types of resins.

[Table of Contents](#)

Net Loss

Net loss increased by \$890,181 or 362.1%, to \$1,135,987 for the three months ended September 30, 2006 compared to the three months ended September 30, 2005. Net loss increased by \$1,475,040 or 226.4%, to \$2,126,499 for the nine months ended September 30, 2006 compared to the nine months ended September 30, 2005. This increase in net loss was a result of increased G&A expenses and professional fees for our growth. Currently operating costs exceed revenue because sales are not yet significant. We cannot assure when or if revenue will exceed operating costs.

Liquidity and Capital Resources

The Company had net cash of \$154,738 at September 30, 2006.

The Company had working capital equity (i.e. the difference between current assets and current liabilities) of \$489,651 at September 30, 2006.

During the nine months ended September 30, 2006, the Company used \$2,303,318 of cash for operating activities. The increase in the use of cash for operating activities was a result of hiring staff, professional fees incurred, significant acquisition of inventory, and marketing expenses.

Cash used in investing activities to purchase equipment during the nine months ended September 30, 2006 was \$565,335

Cash provided by financing activities relating to the issuance of shares of common stock during the nine months ended September 30, 2006 was \$2,516,904. On, February 13, 2006 the Company entered into an equity financing agreement, in which 5,000,000 shares of common stock were issued for an Equity Line of Financing in the amount of \$10,000,000. As of September 30, 2006, the Company had drawn \$625,000 in exchange for 720,698 shares, giving the Company availability of \$9,375,000 under the Equity Line of Financing.

Item 3. Controls and Procedures

As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. There was no change in our internal controls or in other factors that could affect these controls during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

[Table of Contents](#)

PART 2 — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company's business. The Company is currently not aware of nor has any knowledge of any such legal proceedings or claims that we believe will have, individually or in the aggregate, a material adverse affect on our business, financial condition or operating results.

ITEM 2. ISSUANCE OF UNREGISTERED SECURITIES AND USE OF PROCEEDS

We have issued the following unregistered securities during the nine months the ended September 30, 2006.

- The Company sold 1,050,000 restricted shares of common stock at \$0.10 per share to accredited investors for aggregate consideration of \$105,000 during the first quarter.
- The Company sold 10,710,000 restricted shares of common stock at \$0.1238 per share to accredited investors for aggregate consideration of \$1,326,250 during the first quarter.
- On October 4, 2006, the Company received funds of \$200,000 in exchange for 500,000 restricted shares.

All of the above offerings and sales were deemed to be exempt under rule 506 of Regulation D and Section 4(2) of the Securities Act of 1933, as amended. No advertising or general solicitation was employed in offering the securities. The offerings and sales were made to a limited number of persons, all of whom were accredited investors, business associates of our company or executive officers of the Company, and transfer was restricted by the Company in accordance with the requirements of the Securities Act of 1933. In addition to representations by the above-referenced persons, we have made independent determinations that all of the above-referenced persons were accredited or sophisticated investors, and that they were capable of analyzing the merits and risks of their investment, and that they understood the speculative nature of their investment. Furthermore, all of the above-referenced persons were provided with access to the Company's Securities and Exchange Commission filings.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES:

Not Applicable

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

Not Applicable

ITEM 5. OTHER INFORMATION

Not Applicable

ITEM 6. EXHIBITS

31.1 Certification by the Chief Executive Officer and Principal Accounting/Financing Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1 Certification by the Chief Executive Officer and Principal Accounting/Financing Officer Pursuant to 18 U.S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

[Table of Contents](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CEREPLAST, INC.

By: /s/ Frederic Scheer
Frederic Scheer
President, Chief Executive Officer,
Principal Financial/Accounting Officer
and Chairman

Dated: November 14, 2006